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A B S T R A C T
Minocycline, a tetracycline family antibiotic, is known to inhibit microglial activation and
proinﬂammatory cytokine release in animal models. Experimental data show that these immune
processes may play a role in epilepto- and ictogenesis. We present the case of a patient with marked
reduction in seizure frequency during minocycline therapy with severe symptomatic epilepsy due to an
astrocytoma.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Minocycline is a second-generation tetracycline antibiotic with
anti-inﬂammatory effects.1 Its mechanisms of action in the central
nervous system (CNS) include suppression of microglia and T cell
activation2 as well as reduced proinﬂammatory cytokine release.3
Activated microglia and interleukin release have been implicated
in epileptogenesis and ictogenesis in animal models,4 however
experimental evidence is more convincing for cases of ictogenesis
rather than epileptogenesis. We present a case suffering from drug
resistant symptomatic focal epilepsy with frequent seizures who
achieved almost complete seizure freedom after treatment with
minocycline.
2. Case report
A 53 years-old retired ofﬁce employee was seen in the
outpatient clinic of our epilepsy centre for the ﬁrst time in
2006. In 1998 he had undergone resection of an astrocytoma
WHO II8 in the right supplementary motor area with residual
mild left-sided hemiparesis and reduced word ﬂuency due
to right-hemispheric language dominance. Additionally, a
melanoma at the right shoulder was diagnosed and resected
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sensory aura in the left leg followed by clonic movements of the
left leg and, rarely, by secondary generalisation. Various antiepi-
leptic drugs (AEDs) were sequentially administered with little or
no effect: carbamazepine (up to 1200 mg/d), oxcarbazepine (up
to 450 mg/d), topiramate (up to 75 mg/d), levetiracetam (up to
4000 mg/d), pregabaline (up to 600 mg/d), lamotrigine (up to
500 mg/d), zonisamide (up to 300 mg/d), eslicarbazepine acetate
(up to 2000 mg/d) and lacosamide (up to 300 mg/d).
Six monthly follow-up MRI scans showed no growth of the
astrocytoma until February 2010, when imaging suggested
malignant transformation of the tumor. A biopsy at this stage
revealed a WHO III8 astrocytoma. The patient was treated with
radiotherapy (60 Gy, March to May 2010) and concomitant
adjuvant temozolomide chemotherapy. These treatments were
not associated with a notable change in seizure frequency.
In addition, dexamethasone 4 mg/d was started in May 2010
which led to a marked decrease in seizure frequency (from an
average of 5–7 seizures/week to 1 seizure/week). At this point, his
antiepileptic medication remained unchanged and consisted of
lamotrigine 300 mg/d, levetiracetam 4000 mg/d and eslicarbaze-
pine acetate 2000 mg/d. During follow up, the patient developed
Cushing syndrome and asked whether dexamethasone could be
withdrawn. After discontinuation of dexamethasone seizure
frequency deteriorated dramatically with 10–20 seizures/day
despite triple AED combination.
In this situation minocycline 50 mg b.i.d was added for an off-
label indication because of its known anti-inﬂammatory effects.
This rendered the patient completely seizure free within one weekvier Ltd. All rights reserved.
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only one seizure during the second month but developed acne
vulgaris, dermal ablation and a furuncle which was interpreted as
minocycline adverse effects. Minocycline was stopped which
improved the skin eruptions but his epilepsy worsened again with
daily clonic seizures of the left side. With re-introduction of
dexamethasone 12 mg/d, the frequency of seizures dropped to a
low level of one seizure every two weeks. Throughout the
treatment period no change in the small tumor oedema, which
could itself provoke seizures, was seen.
In December 2010, the patient developed pulmonary and bone
metastases of his melanoma and received palliative therapy. While
the size of the astrocytoma remained stable, a new cerebral lesion
was detected in July 2011 which was a probable metastasis of the
melanoma. At last follow-up, he suffered still from one clonic
seizure per day under zonisamide 300 mg/d, lamotrigine 300 mg/d
and levetiracetam 4000 mg/d and dexamethasone 4 mg/d.
3. Discussion
The present case suggests that minocycline can have anticon-
vulsant properties in humans which may be due to its anti-
inﬂammatory mode of actions.1
Minocycline is known to cross the blood-brain barrier (BBB).5 In
animal models of seizures, minocycline was shown to inhibit
seizure susceptibility, hippocampal IL-1b levels, and glutamate
receptor subunit expression,6 and protect against hippocampal cell
death induced by kainate acid treatment through inhibition of
caspase-dependent and – independent pathways.7
Peripheral injection of minocycline could reduce seizure
susceptibility in rodents probably due to suppression of IL-1b
release from microglia.6 In addition, its ability to inhibit activated
microglia may contribute to the anticonvulsant effects as
experimental data showed that hippocampal neurogenesis was
restored through inhibition of microglial activation in epileptic
rats.8
This adds further evidence to the impression that modulating
immune processes can have anticonvulsant effects in human
epilepsy9 as already implied by the long-standing clinical
experience that cortisone/ACTH has anticonvulsive effects inchildhood and adult epilepsy including West syndrome and status
epilepticus.10
Based on this case report, we hypothesize that the effects of
minocycline on IL-1b release and microglial activation can play a
signiﬁcant role in human epilepsy and that inhibiting these
processes is anticonvulsive. However, it remains unclear whether
tumor-induced epilepsy is especially or uniquely susceptible to
immune modulating therapy as compared with other etiologies.
Further prospective studies are necessary to verify or falsify the
hypothesis raised from this case report.
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